A Global Imatinib and Nilotinib Pregnancy Exposure Registry

Completed

Conditions studied: All Indications for Glivec/Gleevec and Tasigna

In brief

This is a voluntary, international, primarily prospective, observational, exposure-registry and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six months prior to pregnancy.

Key facts

Study ID

NCT01289054

Run by

Novartis Pharmaceuticals

People needed

4

Starts

2011-01-01

Expected to finish

2015-03-01

Last updated by the study team

2015-04-15

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Provide sufficient evidence to confirm that exposure occurred during pregnancy or within 6 months prior to exposure.
• Be at least 18 years of age
• Reside in a country supported by the Registry

You may not qualify if…

• Cases that do not meet the eligibility criteria are deemed ineligible, including paternal exposures
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• INC Research, LLC — Wilmington, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.